Latest research on Aspart

Insulin aspart is a recombinant, biosynthetic, fast-acting insulin analogue. It has a single amino acid substitution at position B28 where proline is replaced with aspartic acid. This substitution decreases its propensity to form hexamers and gives it a higher rate of absorption following subcutaneous administration compared to native insulin. Insulin aspart is produced in a genetically modified strain of _Saccharomyces cerevisiae_ and harvested from a bioreactor.

Latest findings

As patient had the lowest grade of sensitisation to Aspart Insulin according to skin tests, and rapid insulin was needed, a desensitisation with Aspart insulin was proposed to him. [source, 2005]
Since his high requirement of insulin and risk of ketoacidosis, treatment with endovenous regular insulin was continued up to achieve enough dose of Aspart insulin to sustain him. [source, 2005]
Aspart has Aspartate in position 28 of beta chain instead of PROLINE (figure 4). [source, 2005]